Patents by Inventor Karl F. Johnson
Karl F. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200024628Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.Type: ApplicationFiled: May 17, 2019Publication date: January 23, 2020Inventors: Karl F. Johnson, Shawn DeFrees, Stephen Withers, Mark Vaughan
-
Patent number: 10294504Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.Type: GrantFiled: June 29, 2015Date of Patent: May 21, 2019Assignees: La Jolla Pharmaceutical Company, The University of British ColumbiaInventors: Karl F. Johnson, Shawn Defrees, Stephen Withers, Mark Vaughan
-
Publication number: 20160032342Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.Type: ApplicationFiled: June 29, 2015Publication date: February 4, 2016Applicants: Seneb Biosciences, Inc., The University of British ColumbiaInventors: Karl F. JOHNSON, Shawn DEFREES, Stephen WITHERS, Mark VAUGHAN
-
Patent number: 9068208Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.Type: GrantFiled: July 24, 2013Date of Patent: June 30, 2015Assignee: Seneb Biosciences, Inc.Inventors: Karl F. Johnson, Shawn Defrees, Stephen Withers, Mark Vaughan
-
Patent number: 8822191Abstract: The present invention provides methods of refolding mammalian glycosyltransferases that have been produced in bacterial cells, and methods to use such refolded glycosyltransferases, including glycosyltransferase mutants that have enhanced ability to be refolded. The invention also provides methods of refolding more than one glycosyltransferase in a single vessel, methods to use such refolded glycosyltransferases, and reaction mixtures comprising the refolded glycosyltransferases.Type: GrantFiled: February 4, 2005Date of Patent: September 2, 2014Assignee: Novo Nordisk A/SInventors: Sami Saribas, David Hakes, Scott Willett, Karl F. Johnson, Daniel James Bezila, Shawn DeFrees
-
Publication number: 20140147891Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.Type: ApplicationFiled: July 24, 2013Publication date: May 29, 2014Applicants: The University of British Columbia University- Industry Liaison Office, Seneb BioSciences, Inc.Inventors: Karl F. Johnson, Shawn Defrees, Stephen Withers, Mark Vaughan
-
Patent number: 8043833Abstract: The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment.Type: GrantFiled: September 6, 2006Date of Patent: October 25, 2011Assignee: Novo Nordisk A/SInventors: Marc F. Schwartz, Bingyuan Wu, Aliakbar Mobasseri, Shawn A. DeFrees, Tarik Soliman, Karl F. Johnson
-
Publication number: 20090298121Abstract: The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment.Type: ApplicationFiled: September 6, 2006Publication date: December 3, 2009Inventors: Marc F. Schwartz, Bingyuan Wu, Aliakbar Mobasseri, Shawn A. DeFrees, Tarik Soliman, Karl F. Johnson
-
Publication number: 20090170155Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.Type: ApplicationFiled: June 1, 2005Publication date: July 2, 2009Applicant: THE UNIVERSITY OF BRITISH COLUMBIA UNIVERSITY-INDUInventors: Karl F. Johnson, Shawn Defrees, Stephen Withers, Mark Vaughan
-
Patent number: 7524655Abstract: This invention provides nucleic acid and amino acid sequences of fucosyltransferases from Helicobactor pylori. The invention also provides methods to use the fucosyltransferases to synthesize oligosaccharides, glycoproteins, and glycolipids.Type: GrantFiled: December 6, 2005Date of Patent: April 28, 2009Assignees: Neose Technologies, Inc., Governors of the University of AlbertaInventors: Karl F. Johnson, Daniel James Bezila, Diane E. Taylor, Joanne Simala-Grant, David Rasko
-
Publication number: 20080206810Abstract: The present invention features compositions and methods related to truncated mutants of ST6GalNAcI. In particular, the invention features truncated human, mouse, and chicken ST6GalNAcI polypeptides. The invention also features nucleic acids encoding such truncated polypeptides, as well as vectors, host cells, expression systems, and methods of expressing and using such polypeptides.Type: ApplicationFiled: June 3, 2005Publication date: August 28, 2008Applicant: Neose Technologies, Inc.Inventors: Karl F. Johnson, David James Hakes, Ge Wei, Li Liu, Sami Saribas, Eric R. Sjoberg, Henrik Clausen, Eric Paul Bennett, Aliakbar Mobasseri
-
Patent number: 7368108Abstract: This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a homogeneous glycosylation pattern.Type: GrantFiled: November 27, 2002Date of Patent: May 6, 2008Assignee: Neose Technologies, Inc.Inventors: Shawn DeFrees, Karl F. Johnson
-
Publication number: 20080058245Abstract: The present invention relates to methods of providing a protein product to a customer. In particular, the invention relates methods of using protein expression vectors to produce proteins to be provided to a client. The invention also provides vectors for the cloning and expression of proteins, including reagent proteins and therapeutic proteins.Type: ApplicationFiled: January 6, 2005Publication date: March 6, 2008Inventors: Karl F. Johnson, Dan Bezila, Winnie Ngo, David Hakes
-
Patent number: 7326770Abstract: This invention provides nucleic acid and amino acid sequences of fucosyltransferases from Helicobactor pylori. The invention also provides methods to use the fucosyltransferases to synthesize oligosaccharides, glycoproteins, and glycolipids.Type: GrantFiled: January 22, 2004Date of Patent: February 5, 2008Assignees: Neose Technologies, Inc., Governors of the University of AlbertaInventors: Joanne Simala-Grant, Diane Taylor, Karl F. Johnson, Daniel James Bezila
-
Publication number: 20030207406Abstract: The present invention relates to a method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and a gene encoding such a polyglycosyltransferase.Type: ApplicationFiled: March 7, 2002Publication date: November 6, 2003Applicant: Neose Technologies, Inc.Inventors: Karl F. Johnson, Stephen Roth, Stephanie L. Buczala
-
Patent number: 6379933Abstract: The present invention relates to a method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and a gene encoding such a polyglycosyltransferase.Type: GrantFiled: June 24, 1999Date of Patent: April 30, 2002Assignee: Neose Technologies, Inc.Inventors: Karl F. Johnson, Stephen Roth, Stephanie L. Buczala
-
Patent number: 6127153Abstract: The present invention relates to a method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and a gene encoding such a polyglycosyltransferase.Type: GrantFiled: June 7, 1995Date of Patent: October 3, 2000Assignee: Neose Technologies, Inc.Inventors: Karl F. Johnson, Stephen Roth, Stephanie L. Buczala
-
Patent number: 6001819Abstract: The present invention is directed to compositions for the treatment of respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenza, Burkholderia (Pseudomonas) cepacia, and a mixture thereof, comprising a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc-, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;R.sub.9 is NH--C.sub.1-6 acyl, glycolylamido, amino or hydroxyl; andA is H or a cation;R.sub.2 is H or (.alpha.-1)Fuc-;R.sub.3 and R.sub.4 are each independently OH or NHAc;R.sub.5 is H, SO.sub.Type: GrantFiled: April 3, 1998Date of Patent: December 14, 1999Assignee: Neose Technologies, Inc.Inventors: Paul M. Simon, David Zopf, Roger A. Barthelson, Karl F. Johnson
-
Patent number: 5736533Abstract: The present invention is directed to a method of treating respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenzae, Burkholderia (Pseudomonas) cepacia and a mixture thereof, by administering a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc--, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;R.sub.9 is NH--C.sub.1-6 acyl, glycolylamido, amino or hydroxyl; andA is H or a cation;R.sub.2 is H or (.alpha.-1)Fuc--;R.sub.3 and R.sub.4 are each independently OH or NHAc;R.sub.5 is H, SO.sub.Type: GrantFiled: June 7, 1995Date of Patent: April 7, 1998Assignee: Neose Technologies, Inc.Inventors: Paul M. Simon, David Zopf, Roger A. Barthelson, Karl F. Johnson
-
Patent number: H1633Abstract: A deodorized polysulfide composition, comprising a major amount of polysulfide material and a minor but effective amount of a deodorizing composition comprising an oil-soluble tertiary alkanolamine of the formula: ##STR1## wherein R.sub.2, R.sub.3 and R.sub.4 are independently alkyl groups of about 1 to 6 carbon atoms; and a monohydric alkyl alcohol containing up to about 12 carbon atoms is disclosed.Type: GrantFiled: March 8, 1995Date of Patent: February 4, 1997Assignee: The Lubrizol CorporationInventors: Gregory L. Hiebert, Karl F. Johnson